EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety and Effectiveness of Ustekinumab for Crohn’s Disease in Japanese Post-marketing Surveillance in Biologic-Naive and -Experienced Conriemed

Katsumasa Nagano iD, Erina Hata, Teita Asano, Hiroaki Tsuchiya, Masayuki Takagishi, Hiroshi Yamazaki, Sonoko Tominaga, Takayuki Matsumoto

Crohn's & Colitis 360 · 01.01.2023 · 5 (1)

DOI: 10.1093/crocol/otad001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Crohn's & Colitis 360, online erschienen am 12.01.2023. Verfasst von Katsumasa Nagano und 7 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Pharmaceutical K.K., Medical affairs division, Tokyo, Japan. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Pharmaceutical K.K., Tokyo, Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To present the real-world evidence on the safety and effectiveness of ustekinumab (UST) through 52-week treatment for Crohn’s disease (CD) under an analysis of post-market surveillance data in Japan.

Methods

This prospective, post-marketing surveillance study was conducted in 341 patients from 91 medical facilities in Japan. Patients received UST 90 mg injected subcutaneously once every 12 weeks (or every 8 weeks if patients show weak effectiveness) after an induction dose given intravenously. Clinical response (100-point decrease in Crohn’s Disease Activity Index [CDAI] score), clinical remission (CDAI score of <150), steroid-free clinical remission, C-reactive protein, endoscopy, physician global assessment, and adverse drug reactions (ADRs) were evaluated through 52 weeks.

Results

The overall rate of clinical remission was 49.2% at week 8 and 56.0% at week 52. The rate of clinical remission in biologic-naive patients was 75.9% and 66.7% at weeks 8 and 52, respectively, whereas the rate in biologic-experienced patients was 41.4% and 52.6% at weeks 8 and 52, respectively. For 52 weeks, the overall incidence of ADRs and serious adverse drug reactions (SADRs) was 11.7% and 6.7%, respectively. The most frequently reported SADRs was worsening of CD (1.8%). In multivariate analysis, ADRs incidence was significantly lower in patients with ileal involvement of CD (odds ratio = 0.25, 95% CI 0.07–0.85, P = .026), although disease location has no association with effectiveness of UST.

Conclusions

The present study identified no new safety concerns and effectiveness for CD in Japanese patients treated with UST.

Schlagwörter

Stichwörter der Autor:innen

Crohn’s Disease Activity Indexbio-experiencedbio-naiveustekinumab

Autor:innen und Institutionen

  • Janssen Pharmaceutical K.K., Medical affairs division, Tokyo, Japan.
  • Janssen Pharmaceutical K.K., Research & Development division, Tokyo, Japan.
  • Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Iwate, Japan.

ORCID-Profile: Katsumasa Nagano

Förderung

  • Janssen Pharmaceutical K.K., Tokyo, Japan

Zitieren

APA

Nagano, K., Hata, E., Asano, T., Tsuchiya, H., Takagishi, M., Yamazaki, H., Tominaga, S., & Matsumoto, T. (2023). Safety and Effectiveness of Ustekinumab for Crohn’s Disease in Japanese Post-marketing Surveillance in Biologic-Naive and -Experienced Conriemed. Crohn's & Colitis 360, 5(1). https://doi.org/10.1093/crocol/otad001

Vancouver

Nagano K, Hata E, Asano T, Tsuchiya H, Takagishi M, Yamazaki H, et al. Safety and Effectiveness of Ustekinumab for Crohn’s Disease in Japanese Post-marketing Surveillance in Biologic-Naive and -Experienced Conriemed. Crohn's & Colitis 360. 2023;5(1). doi:10.1093/crocol/otad001

BibTeX
@article{Nagano2023,
  author = {Nagano, Katsumasa and Hata, Erina and Asano, Teita and Tsuchiya, Hiroaki and Takagishi, Masayuki and Yamazaki, Hiroshi and Tominaga, Sonoko and Matsumoto, Takayuki},
  title = {Safety and Effectiveness of Ustekinumab for Crohn’s Disease in Japanese Post-marketing Surveillance in Biologic-Naive and -Experienced Conriemed},
  journal = {Crohn's & Colitis 360},
  year = {2023},
  volume = {5},
  number = {1},
  doi = {10.1093/crocol/otad001}
}
Kostenlos starten →